Lucid Diagnostics price to sales ratio LUCD

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 15.3×
4-year median: 29.3×
Against its 4-year history: 22nd; percentile: 0 is its lowest day, 100 its highest
4-year range: 11.1× to 146×
Peer median: 1.6×

Lucid Diagnostics' price to sales ratio is 15.3× as of Oct 23, 2026.

That is below its 4-year median of 29.3×, lower than on 78% of days in the last 4 years.

Over that time it ranged from 11.1× in Dec 2024 to 146× in Aug 2022.

The median for 10 medical instruments and supplies stocks of a similar size is 1.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.3×	15.3×	47.0×
2025	34.1×	11.6×	36.3×
2024	11.2×	11.1×	18.8×
2023	88.0×	72.7×	88.0×
2022	77.2×	77.2×	146×

Against its peers

Companies in Medical - Instruments & Supplies nearest Lucid Diagnostics' size, closest first, today.

Company	Price to sales ratio
LUCDLucid Diagnostics	15.3×
KEQUKewaunee Scientific	0.3×
APTAlpha Pro Tech	0.9×
NEPHNephros	1.9×
PDEXPro DEX	2.6×
UTMDUtah Medical Products	6.5×
INFUInfuSystem	1.9×
EMBCEmbecta	0.4×
TCMDTactile Systems Technology	1.5×
MDXGMimedx	1.6×
MOVMovado	1.0×
Peer median	1.6×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Lucid Diagnostics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.